

RESEARCH

Open Access



Effect of glycosylation on the affinity of the MTB protein Ag85B for specific antibodies: towards the design of a dual-acting vaccine against tuberculosis

Roberta Bernardini^{1,2*†}, Sara Tengattini^{3*†}, Zhihao Li⁴, Luciano Piubelli⁵, Teodora Bavaro³, Anamaria Bianca Modolea², Maurizio Mattei^{2,6}, Paola Conti⁷, Stefano Marini¹, Yongmin Zhang⁴, Loredano Pollegioni⁵, Caterina Temporini³ and Marco Terreni³

Abstract

Background To create a dual-acting vaccine that can fight against tuberculosis, we combined antigenic arabinomannan analogues with the Ag85B protein. To start the process, we studied the impact of modifying different parts of the Ag85B protein on its ability to be recognized by antibodies.

Results Through our research, we discovered that three modified versions of the protein, rAg85B-K30R, rAg85B-K282R, and rAg85B-K30R/K282R, retained their antibody reactivity in healthy individuals and those with tuberculosis. To further test the specificity of the sugar AraMan for AraMan antibodies, we used Human Serum Albumin glycosylated with AraMan-IME and Ara₃Man-IME. Our findings showed that this specific sugar was fully and specifically modified. Bio-panning experiments revealed that patients with active tuberculosis exhibited a higher antibody response to Ara₃Man, a sugar found in lipoarabinomannan (LAM), which is a major component of the mycobacterial cell wall. Bio-panning with anti-LAM plates could eliminate this increased response, suggesting that the enhanced Ara₃Man response was primarily driven by antibodies targeting LAM. These findings highlight the importance of Ara₃Man as an immunodominant epitope in LAM and support its role in eliciting protective immunity against tuberculosis. Further studies evaluated the effects of glycosylation on the antibody affinity of recombinant Ag85B and its variants. The results indicated that rAg85B-K30R/K282R, when conjugated with Ara₃Man-IME, demonstrated enhanced antibody recognition compared to unconjugated or non-glycosylated versions.

[†]Roberta Bernardini and Sara Tengattini contributed equally to this work.

*Correspondence:
Roberta Bernardini
roberta.bernardini@uniroma2.it
Sara Tengattini
sara.tengattini@unipv.it

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Conclusions Coupling Ara₃Man to rAg85B-K30R/K282R could lead to the development of effective dual-acting vaccines against tuberculosis, stimulating protective antibodies against both AraMan and Ag85B, two key tuberculosis antigens.

Keywords Lipoarabinomannan, Tuberculosis, *Mycobacterium*, Glycoconjugate, Antibodies, Vaccine, Immune response

Introduction

Tuberculosis (TB) is a significant global health challenge, with over 10 million new cases and 1.5 million deaths reported annually [1]. Drug resistance is a major obstacle to TB control. Multi-drug-resistant TB (MDR-TB) represents the pathological condition resistant to both isoniazid and rifampicin, the two most potent first-line anti-TB drugs. Extensively drug-resistant TB (XDR-TB) is even more resilient, with resistance to at least three of the six most effective anti-TB drugs [2]. Numerous studies have been conducted on the protein domains involved in both host and pathogen proteins involved in the infection mechanism [3] and host-directed therapies (HDTs) are a new approach to TB treatment that targets the host's immune system to help it fight the infection. HDTs have shown promise in early clinical trials, but they are still in development [4, 5]. Vaccines are the most effective way to prevent infectious diseases, including TB. However, the only licensed TB vaccine, Bacille Calmette-Guérin (BCG), is not effective enough in preventing TB disease in adults. BCG is more effective in preventing TB meningitis in children, but it does not provide long-term protection against pulmonary TB [6, 7].

Extensive research has been carried out on non-natural glycoproteins and glycolipids to develop new therapeutic approaches for infectious diseases and cancer [8, 9]. Carbohydrate-based vaccines have been investigated as a potential treatment option [10–13]. To create anti-infective vaccines, antigenic oligosaccharides naturally present on the pathogen's membrane are chemically conjugated with specific immunogenic carrier proteins like diphtheria toxoid, tetanus toxoid, and cross-reactive material 197 (a mutant form of diphtheria toxoid) [14, 15]. The use of natural oligosaccharides obtained from pathogens allowed the development of effective vaccines against different serotypes of *Haemophilus influenzae* type b (Hib) virus and *Streptococcus pneumoniae*, or *Neisseria meningitidis* [16] and more recently Varicella-zoster virus [17]. Synthetic oligosaccharides have been used as an alternative for the preparation of a vaccine against Hib [18] to avoid the problems related to the production of pure oligosaccharides from natural sources.

Arabinomannan (AM) is the major carbohydrate antigen of MTB and is part of the lipoarabinomannan (LAM) membrane glycolipids. This oligosaccharide has been considered for the development of new glycovaccines against TB. However, it is very complex and difficult to

be prepared by total synthesis. For this reason, synthetic analogues have been recently investigated as antigens for the development of carbohydrate-based TB vaccines [19–22].

New synthetic strategies are continuously proposed to reduce the drawbacks of the chemical synthesis of oligosaccharides. In this context, biocatalysis is considered an important tool to reduce the synthetic steps [23]. In past years, we have developed enzymatic strategies for the synthesis of acetylated sugar building blocks with free hydroxyl groups at desired position [24, 25] that can be then chemically assembled to obtain complex oligosaccharides using the acetyl as the only protecting group [26]. This approach has been recently employed for the chemoenzymatic synthesis of antigenic AM analogues composed by the combination of different units of mannose and arabinose [19].

On the other hand, subunit vaccines obtained by gene fusion of different antigenic TB proteins are under investigation. Ag85B, the major protein antigen of MTB, has been considered for the development of several subunit vaccines that have been submitted to clinical investigation, aiming to develop efficient vaccines alternative to the BCG [27].

Ag85B was also conjugated to natural AM isolated from MTB, to obtain vaccines with high antigenic properties prepared by combining two different MTB antigens [12, 28, 29]. However, the biological activity of neo-glycoproteins based on antigenic proteins could be negatively affected by the glycosylation of the protein epitopes [30, 31]. In fact, the T-cell activity of Ag85B was strongly depressed by chemical glycosylation targeting lysines (the most used approach for the preparation of neo-glycoproteins) regardless the kind of sugar used [30]. Several works dealing with the characterization of the T-cell epitopes of this protein have been published [30, 32]. Still, only a few of them contained data on the characterization of B-cell epitopes recognized by human antibodies [30, 31]. A detrimental effect induced by chemical glycosylation of recombinant Ag85B (rAg85B) on T-cell activity was observed and ascribed to the modification of two lysines involved in relevant epitopes [33]. Accordingly, rAg85B variants obtained by replacement of these lysines with arginines have been designed to avoid their glycosylation. Thus, rAg85B, which bears seven additional amino acid residues at the N-terminal region with respect of the sequence of the wild-type (wt) Ag85B [34], was compared

with its variants obtained by Lys (K) to Arg (R) substitution at position 30 and 282 (corresponding to K23 and K275, respectively). These rAg85B variants maintained the T-cell activity after glycosylation unlike the wild-type rAg85B [33].

Little is known about the effect of glycosylation on the recognition of antigenic protein by human antibodies. Therefore, in order to develop a dual-acting vaccine obtained by conjugation of antigenic AM analogues with Ag85B, here we evaluated the effect induced by glycosylation of rAg85B on the affinity for antibodies present in the serum of TB patients. This work reports the preparation of different neo-glycoproteins using sugars activated with an iminomethoxyethyl (IME) reactive linker and different proteins. The different products were evaluated in the binding of antibodies obtained from patients with active TB and from healthy controls.

Materials and methods

Production of proteins and neo-glycoproteins

Recombinant Ag85B (rAg85B) and its variants (obtained by substitution of a Lys residue with Arg at position 30 and/or 282) were prepared according to the previously reported methods [33, 34]. This approach yields proteins with seven additional amino acid residues at the N-terminal compared to the sequence of the wt Ag85B. Thus, positions 30 and 282 in rAg85B correspond to positions 23 and 275 in the sequence of the wt protein.

The synthesis of the different glycans activated by an IME linker [19, 35], the chemical glycosylation of proteins, and the characterization of the neo-glycoproteins obtained were carried out according to the procedures previously reported for the different supports: commercial recombinant human serum albumin (rHSA, Oryzogen, Wuhan, China) [19], rAg85B [30] and variants [33].

Studied population

The study enrolled 47 individuals with newly diagnosed and untreated active pulmonary tuberculosis, along with 40 healthy individuals with no history of tuberculosis exposure (referred to as TB unexposed controls). In all cases, the diagnosis of active TB was confirmed through *M. tuberculosis* culture isolation.

ELISA assay

Antibodies against Ag85B proteins and their glycode derivatives were detected using an ELISA assay with minor modifications based on a previously described protocol [36].

The ELISA assay was performed in 96-well microplates (Nunc Maxisorb, Becton Dickinson). The antigens (recombinant proteins: rAg85B, rAg85B-K30R, rAg85B-K282R, rAg85B-K30R/K282R, synthesized oligosaccharides: AraMan, Ara₃Man, Man₂ and the

conjugated glycoproteins: rAg85B+Man₂, rAg85B-K30R/K282R+Man₂, rAg85B-K30R/K282R+Ara₃Man).

were diluted to a final concentration of 10 µg/mL in 100 µL of carbonate buffer (pH 9.6) and incubated for 2 h at room temperature followed by overnight incubation at 4 °C. The wells were then washed twice with phosphate-buffered saline (PBS) containing 0.05% Tween-20 (PBS-T) to remove any unbound proteins.

To block the non-specific binding sites, the wells were incubated (37 °C, 1 h) with PBS-T containing 3% bovine serum albumin (BSA). Subsequently, the plates were incubated for 1 h at room temperature with 100 µL of serum diluted 1:100.

For the ELISA panning assay, plates were coated with lipoarabinomannan (LAM BEI Resources, NIAID, USA) diluted (final concentration 2 µg/mL) in 100 µL of carbonate buffer (pH 9.6), then incubated, washed and blocked using the same procedure described before. The sera were incubated (RT, 1 h) with 100 µL of serum (1:100), and the procedure was repeated three times (in three different plates subsequently), keeping all other conditions identical as before. After the incubation with sera, all the plates (those analyzed with the antigens and those analyzed with LAM for the panning) were incubated (RT, 1 h) with anti-human IgG Secondary Antibody HRP conjugated (Invitrogen, Italy). The absorbance (OD) at 492 nm of antigen- and buffer-coated wells was measured, and the difference in mean OD values was calculated. All samples were assayed in duplicate to increase precision.

Statistical analysis

Data were reported as the mean values ± standard error of the mean (SEM) or standard deviation (SD). Statistical comparisons between two groups were performed by Student's t-test. *p* values < 0.05 were considered to be statistically significant. GraphPad Prism version 5.0 (GraphPad Software, Inc., La Jolla, CA) was used for all statistical analyses and graphs.

Results

Ag85B variants preserved the antibody reactivity in healthy and TB human samples

To evaluate the impact of substitutions of Lys30 and/or Lys282 of Ag85B with arginine (rAg85B-K30R, rAg85B-K282R and rAg85B-K30R/K282R, respectively), sera from control and TB subjects were investigated. Control sera indicated comparable antibody levels against rAg85B and its variants (Fig. 1), except a slightly higher value for the K282R variant. In TB patients, significantly increased antibody levels were detected for rAg85B and its variants, compared to controls. This enhancement in TB patients was uniform for each antibody (+50–80%) relative to each control; no significant difference was observed




Fig. 1 Levels of antibodies (IgG) reactive against the rAg85B and its variants in TB patients (TB: 47 samples) and healthy subjects (CTR: 40 samples). All samples were measured in duplicate and repeated three times. The data are presented as mean values \pm standard error of the mean (SEM). OD = optical density; * = $p \leq 0.05$ by Student's t-test

between rAg85B and its variants in TB patients. This analysis demonstrates that, while antibody levels against the different rAg85B variants are increased in TB vs controls, no significant differences can be detected when normal subjects were compared. Therefore, the introduced substitutions do not alter the antibody response.

Preparation and characterization of neo-glycoproteins

The Man₂, AraMan and Ara₃Man glycans, activated in an anomeric position with the IME reactive linker (Fig. 2a), which selectively targets the amino group of lysine residues [35], were used to prepare the different neo-glycoproteins (Fig. 2b) considered in the evaluation of antibody affinity.

After conjugation, the degree of glycosylation of the resulting neo-glycoproteins was determined by analyzing the residual presence of unmodified protein and the average glycan loading.

For rHSA derivatives, conjugation was assessed by hydrophilic interaction liquid chromatography (HILIC) and high-resolution mass spectrometry (HRMS), as previously described [19]. Both samples, AraMan and Ara₃Man, showed the complete modification of rHSA and an average loading of 9.3 and 14.5 [19] mol/mol, respectively.

For Man₂-rAg85B the conjugation was quantitative, with no residual presence of unmodified protein and an average loading of 4.8 disaccharide units *per* protein. The substitution of lysine 30 and 282 significantly reduced protein reactivity, as previously described [33], yielding

to a 98% glycosylation degree and an average loading of 2.5 mol/mol. To compensate the further reduction of reactivity due to the increased saccharide size, the glycan/protein molar ratio was increased to 250:1 in the preparation of Ara₃Man-Ag85B-K30R/K282R. This resulted in 100% glycosylation yield and an average loading of 2.8 mol/mol.

The LAM-specific antibodies were subtracted by three rounds of bio-panning

To characterize the antibody reactivity to the AM mimetic sugar antigen, the AraMan and Ara₃Man motifs were examined after conjugation with HSA. Control and TB sera were placed into wells containing a non-immunogenic protein (HSA) or the same protein glycosylated with the disaccharide (AraMan-rHSA) or the tetrasaccharide (Ara₃Man-rHSA). To determine whether antibodies against these motifs were specific for LAM, negative affinity purification of antibodies was also performed. In detail, samples of sera were placed into wells containing LAM for three rounds of subtractive (negative) panning *in vitro*. Sera negativity to rHSA was tested by ELISA in the same experiment.

Before the panning, the ELISA test showed a higher Ara₃Man antibodies level in TB subjects compared to experiments performed with the non-glycosylated protein and with the disaccharide AraMan ($p < 0.0037$ and $p < 0.0031$ respectively) (Fig. 3). However, this difference disappeared after three rounds of bio-panning; the reduction in the response against Ara₃Man was statistically




Fig. 3 ELISA analysis. **(a)** ELISA analysis for the determination of antibody (IgG) levels against HSA, Ara₃Man-rHSA and AraMan-rHSA was carried out using samples obtained before and after three rounds of selection against LAM in healthy subjects (CTR) and in TB patients. Absorbance values are the mean of 9 control samples and 11 TB samples in each group. All samples were measured in duplicate and repeated three times. Error bars show standard error of the mean (SEM) for each set of data. $*=p \leq 0.05$ by Student's t-test. The level of antibodies against Ara₃Man is very high in TB patients, and is reduced by about 50% in TB patients when LAM post-adsorption serum was tested. **(b, c)** Detection of anti-LAM antibody level upon 3 bio-panning procedures. The level of specific antibodies against LAM was measured after each bio-panning step. The same sera were tested on three adsorbed LAM plates consecutively (from Plate LAM 1 to Plate LAM 3); the reduction is expressed in OD mean values \pm standard error of the mean (SEM) **(b)** and in percentage **(c)** of healthy control and TB subjects **(b)** or only TB **(c)**, respectively. High levels of anti-LAM antibodies are detected in TB patients on bio-panning steps (reduced by about 50% from step 1 to step 3), while no anti-LAM antibodies could be found in healthy controls

Therefore, TB subjects have the highest levels of antibodies with reactivity towards the rAg85B-K30R/K282R variant conjugated with Ara₃Man, due to the synergistic effect of the two antigens (protein and sugar moiety), which may provide the basis for a dual-acting vaccine.

Discussion

In this study, we first analyzed the effect of selected Ag85B modification on antibody recognition. Then, Human Serum Albumin (HSA) glycosylated with AraMan-IME and Ara₃Man-IME was considered to assess the specificity of the last sugar for AM antibodies.

In addition, rAg85B and its variant obtained by K/R substitution at positions 30 and 282 (rAg85BK30R/




Fig. 4 Distribution of antibodies (IgG) levels reactive with rAg85B, its double variant and the corresponding glycoderivatives, in TB patients and healthy subjects (14 TB samples and 17 controls). All samples were measured in duplicate and repeated three times. The data are presented as mean values \pm standard error of the mean (SEM). OD = optical density; CTRL: controls; TB = tuberculosis. $p \leq 0.05 = *$, $p \leq 0.0001 = ****$ were calculated by Student's t-test

K282R) and glycosylated with Man₂-IME was studied to assess the effect of the glycosylation on the antibody affinity of these antigenic proteins. Finally, conjugation of rAg85B-K30R/K282R double variant with Ara₃Man-IME has been investigated as a proof of concept about the potential development of dual-acting vaccines against TB targeting antibodies specific for two different types of MTB antigens (the AM sugar and the Ag85B protein).

Given the success of several carbohydrate-based antibacterial vaccines, including those against facultative intracellular organisms [37–39], we focused our efforts on constructing a carbohydrate-protein conjugate vaccine against TB using an oligosaccharide that mimics the LAM antigen of MTB. For this purpose, Ag85B was selected as the carrier protein in order to design a double-acting vaccine, since it is one of the most potent antigenic species expressed by MTB.

Therefore, a recombinant form of Ag85B (rAg85B) [34] and the K30R and/or K282R variants were prepared. The substitution of these amino acids, which are involved in the main T-cell epitopes of Ag85B, proved to be conservative for protein conformation: ex-vivo ELISPOT experiments demonstrated that all protein variants maintained the original T-cell immunogenic activity exhibited by rAg85B [33]. The activity of the Ag85B variants was also maintained after glycosylation, unlike the wild-type protein, since the introduced substitutions avoid glycosylation of the main T-cell epitopes [33]. In the present work, to complete the evaluation of the immunological response to these recombinant proteins, antibody recognition of wt rAg85B and of its variants was investigated. In an ELISA test, all recombinant

proteins showed similar efficiency of recognition of antibodies present in the serum of MTB-infected patients (Fig. 1). In addition, glycosylation with non-antigenic disaccharide (Man₂ and AraMan) had little effect on the immunoreactivity of these proteins, confirming them as putative antigenic carriers functional for the design of effective glycoconjugated dual-acting vaccines against MTB (Figs. 3a and 4) using a double hit approach (combining sugar and protein antigens).

LAM has been extensively studied for its immunomodulatory properties and as a structurally unique glycolipid component of the envelope of all mycobacterial species [40] and is therefore considered an attractive vaccine candidate [41, 42] to evoke immune responses against MTB. Anti-LAM antibodies are induced during MTB infection [43–45] and have been associated with bacterial opsonization and restriction of intracellular growth [46, 47].

Pure oligosaccharides are poor immunogens as they fail to recruit CD4⁺T cell help. They are therefore limited to T cell-independent B cell immune responses. However, conjugating a bacterial polysaccharide to an immunogenic carrier protein that provides T-cell epitopes creates a T cell-dependent antigen that can induce protective immunity. Indeed, AM isolated from LAM derived from the MTB cell wall and conjugated to various immunogenic carrier proteins has been used to generate new glyco-conjugate TB vaccine candidates [48]. However, AM-conjugated products using different vaccination protocols showed modest protection, never exceeding the effect of BCG vaccination [28, 29, 49–51]. In addition, natural AM is too complex

for chemical synthesis to develop semi-synthetic glyco-vaccines. For this reason, we studied the synthesis of AM analogues structurally related to the natural MTB antigen, which allowed the synthesis of the Ara₃Man that showed affinity to LAM antibodies of infected patients [19].

In the present work, we have demonstrated the specificity of this oligosaccharide for the LAM antibodies of TB patients and its synergic activity towards human TB-antibodies after conjugation with a variant of rAg85B. Actually, ELISA experiments showed that the increased affinity induced by Ara₃Man after conjugation with HSA (Fig. 3) was caused by LAM-specific antibodies. To further validate this specificity, LAM-specific antibodies were selectively removed from TB patient sera using purified LAM from *M. tuberculosis* (Fig. 3). This depletion of LAM-specific antibodies led to a significant decrease in immune recognition of TB samples, confirming the strong correlation between LAM and the Ara₃Man motif.

In addition, the immunogenic activity of rAg85B-K30R/K282R variant conjugated with different synthetic oligosaccharides was investigated. Glycosylation with non-antigenic disaccharides maintained the antibody affinity of the Ag85B variant protein, while conjugation with Ara₃Man tetrasaccharide enhanced it. This improvement was likely due to an additional interaction with LAM-specific antibodies (Fig. 4).

ELISA experiments revealed that TB patients had significantly higher levels of antibodies against the rAg85B-K30R/K282R variant conjugated with Ara₃Man compared to the non-conjugated protein or the one conjugated with Man₂, a non-antigenic disaccharide. These findings suggest that Ara₃Man could serve as a promising glycan component for developing more effective glycoconjugate TB vaccines. By combining Ara₃Man with rAg85B or other relevant antigens, a synergistic effect could be achieved, potentially leading to enhanced immune responses and improved protection against TB. For this reason, the results provide a proof-of-concept for the development of a dual-acting vaccine that targets two different MTB antigens.

The next steps will involve evaluating the immunogenicity of this conjugate in animal models and assessing its protective efficacy after the challenge. Additionally, further investigations will explore alternative AM-mimetic oligosaccharides to optimize the immune response mediated by the sugar antigen.

Acknowledgements

We dedicate this paper to the memory of Prof. Massimo Amicosante, who made a substantial contribution sharing his knowledge with great humanity and professionalism.

Author contributions

Conceptualization, experimental design, RB, ST; writing original draft preparation, RB, ST and MT; design of ex-vivo experiments, RB, MM and SM; ex-vivo experiments, RB and BAM; synthesis of LAM mimetic compounds,

ZL; enzymatic synthesis of sugar building blocks, PC; protein conjugation, TB; protein and glycoprotein analysis, ST; preparation of recombinant Ag85B proteins, LPi and LPo; responsible for protein and glycoprotein analysis, CT; responsible for LAM mimetic synthesis, YZ; responsible for financial support, MT; all authors read and approved the final manuscript.

Funding

This work was partially supported by the Italian Ministry of Health (Project Immunoterapia: cura e prevenzione di malattie infettive e tumorali (Immuno-HUB), project number T4-CN-02).

Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The Ethics Committee of the University of Rome "Tor Vergata" (Rome, Italy) approved the study protocol (protocol number 173/19) "Valutazione biologica Ex Vivo di nuovi glicoconjugati semi-sintetici derivati da proteine antigenetiche ricombinanti di *Mycobacterium tuberculosis* - Ex Vivo biological evaluation of new semi-synthetic glycoconjugates derived from recombinant antigenic proteins of *Mycobacterium tuberculosis*".

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Translational Medicine, University of Tor Vergata, Via Montpellier 1, Rome 00133, Italy

²Interdepartmental Center for Comparative Medicine, Alternative Techniques and Aquaculture (CIMETA), University of Rome "Tor Vergata", Via Montpellier 1, Rome 00133, Italy

³Drug Sciences Department, University of Pavia, Viale Taramelli 12, Pavia 27100, Italy

⁴Parisian Institute of Molecular Chemistry, Sorbonne University, UMR CNRS 8232, 4 Place Jussieu, Paris 75005, France

⁵Department of Biotechnology and Life Sciences, University of Insubria, via J.H. Dunant, 3, Insubria, Varese 21100, Italy

⁶Department of Biology, University of Rome "Tor Vergata", Rome, Italy

⁷Department of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, Milan 20133, Italy

Received: 7 November 2023 / Accepted: 18 January 2024

Published online: 25 January 2024

References

1. <https://www.who.int/teams/global-tuberculosis-programme/data>.
2. Tiberi S, Utjesanovic N, Galvin J, Centis R, D'Ambrosio L, van den Boom M, et al. Drug resistant TB - latest developments in epidemiology, diagnostics and management. *Int J Infect Dis.* 2022;124(Suppl 1):20–55.
3. Zhou H, Gao S, Nguyen NN, Fan M, Jin J, Liu B, et al. Stringent homology-based prediction of *H. sapiens*-*M. Tuberculosis* H37Rv protein-protein interactions. *Biol Direct.* 2014;9:5.
4. Palucci I, Matic I, Falasca L, Minerva M, Maulucci G, De Spirito M, et al. Transglutaminase type 2 plays a key role in the pathogenesis of *Mycobacterium tuberculosis* infection. *J Intern Med.* 2018;283(3):303–13.
5. Palucci I, Salustri A, De Maio F, Pereyra Boza MDC, Paglione F, Sali M et al. Cysteamine/Cystamine exert anti-mycobacterium abscessus activity alone or in combination with Amikacin. *Int J Mol Sci.* 2023;24(2).
6. Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, et al. Progress in Tuberculosis vaccine development and host-directed therapies—a state of the art review. *Lancet Respir Med.* 2014;2(4):301–20.
7. Bishai W, Sullivan Z, Bloom BR, Andersen P. Bettering BCG: a tough task for a TB vaccine? *Nat Med.* 2013;19(4):410–1.

8. Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? *Nat Rev Drug Discov.* 2010;9(4):308–24.
9. Zheng C, Terreni M, Sollogoub M, Zhang Y. Ganglioside GM3 and its role in Cancer. *Curr Med Chem.* 2019;26(16):2933–47.
10. Bernardes GJ, Castagner B, Seeberger PH. Combined approaches to the synthesis and study of glycoproteins. *ACS Chem Biol.* 2009;4(9):703–13.
11. Finco O, Rappuoli R. Designing vaccines for the twenty-first century society. *Front Immunol.* 2014;5:12.
12. Kallenius G, Pawlowski A, Hamasur B, Svenson SB. Mycobacterial glycoconjugates as vaccine candidates against tuberculosis. *Trends Microbiol.* 2008;16(10):456–62.
13. Stallforth P, Lepenies B, Adibekian A, Seeberger PH, Claude S. Hudson Award in Carbohydrate Chemistry. Carbohydrates: a frontier in medicinal chemistry. *J Med Chem.* 2009;52(18):5561–77.
14. Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: a review. *Vaccine.* 2010;28(34):5513–23.
15. Malito E, Bursulaya B, Chen C, Lo Surdo P, Picchianti M, Balducci E, et al. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. *Proc Natl Acad Sci U S A.* 2012;109(14):5229–34.
16. Anderlüh M, Berti F, Bzducha-Wrobel A, Chiodo F, Colombo C, Compostella F, et al. Recent advances on smart glycoconjugate vaccines in infections and cancer. *FEBS J.* 2022;289(14):4251–303.
17. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. *N Engl J Med.* 2016;375(11):1019–32.
18. Verez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo ME, Rodriguez MC, Heynngnezz L, et al. A synthetic conjugate polysaccharide vaccine against *Haemophilus influenzae* type b. *Science.* 2004;305(5683):522–5.
19. Li Z, Bavaro T, Tengattini S, Bernardini R, Mattei M, Annunziata F, et al. Chemoenzymatic synthesis of arabinomannan (AM) glycoconjugates as potential vaccines for tuberculosis. *Eur J Med Chem.* 2020;204:112578.
20. Chang Y, Meng X, Li Y, Liang J, Li T, Meng D, et al. Synthesis and immunogenicity of the *Mycobacterium tuberculosis* arabinomannan-CRM197 conjugate. *Medchemcomm.* 2019;10(4):543–53.
21. Wang L, Feng S, Wang S, Li H, Guo Z, Gu G. Synthesis and immunological comparison of differently linked Lipoarabinomannan Oligosaccharide-Monophosphoryl lipid A conjugates as antituberculosis vaccines. *J Org Chem.* 2017;82(23):12085–96.
22. Wang L, Feng S, An L, Gu G, Guo Z. Synthetic and immunological studies of mycobacterial Lipoarabinomannan oligosaccharides and their protein conjugates. *J Org Chem.* 2015;80(20):10060–75.
23. Hoyos P, Perona A, Bavaro T, Berini F, Marinelli F, Terreni M, et al. Biocatalyzed Synthesis of Glycostructures with anti-infective activity. *Acc Chem Res.* 2022;55(17):2409–24.
24. Filice M, Guisan JM, Terreni M, Palomo JM. Regioselective monodeprotection of peracetylated carbohydrates. *Nat Protoc.* 2012;7(10):1783–96.
25. Filice M, Bavaro T, Fernandez-Lafuente R, Pregolato M, Guisan JM, Palomo JM, et al. Chemo-biocatalytic regioselective one-pot synthesis of different deprotected monosaccharides. *Catal Today.* 2009;140(1–2):11–8.
26. Filice M, Palomo JM, Bonomi P, Bavaro T, Fernandez-Lafuente R, Guisan JM, et al. Preparation of linear oligosaccharides by a simple monoprotective chemo-enzymatic approach. *Tetrahedron.* 2008;64(39):9286–92.
27. Li Z, Zheng C, Terreni M, Tanzi L, Sollogoub M, Zhang Y. Novel vaccine candidates against tuberculosis. *Curr Med Chem.* 2020;27(31):5095–118.
28. Hamasur B, Haile M, Pawlowski A, Schroder U, Williams A, Hatch G, et al. Mycobacterium tuberculosis Arabinomannan-protein conjugates protect against tuberculosis. *Vaccine.* 2003;21(25–26):4081–93.
29. Prados-Rosales R, Carreno L, Cheng T, Blanc C, Weinrick B, Malek A, et al. Enhanced control of *Mycobacterium tuberculosis* extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine. *PLoS Pathog.* 2017;13(3):e1006250.
30. Bavaro T, Tengattini S, Piubelli L, Mangione F, Bernardini R, Monzillo V, et al. Glycosylation of recombinant antigenic proteins from *Mycobacterium tuberculosis*: in Silico Prediction of protein epitopes and Ex Vivo Biological Evaluation of New Semi-synthetic Glycoconjugates. *Molecules.* 2017;22(7).
31. Rinaldi F, Lupu L, Rusche H, Kukacka Z, Tengattini S, Bernardini R, et al. Epitope and affinity determination of recombinant *Mycobacterium tuberculosis* Ag85B antigen towards anti-Ag85 antibodies using proteolytic affinity-mass spectrometry and biosensor analysis. *Anal Bioanal Chem.* 2019;411(2):439–48.
32. Huygen K. The immunodominant T-Cell epitopes of the mycolyl-transferases of the Antigen 85 complex of *M. Tuberculosis*. *Front Immunol.* 2014;5:321.
33. Rinaldi F, Tengattini S, Piubelli L, Bernardini R, Mangione F, Bavaro T, et al. Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity against *Mycobacterium tuberculosis*. *RSC Adv.* 2018;8(41):23171–80.
34. Piubelli L, Campa M, Temporini C, Binda E, Mangione F, Amicosante M, et al. Optimizing *Escherichia coli* as a protein expression platform to produce *Mycobacterium tuberculosis* immunogenic proteins. *Microb Cell Fact.* 2013;12:115.
35. Bavaro T, Filice M, Temporini C, Tengattini S, Serra I, Morelli C, et al. Chemoenzymatic synthesis of Neoglycoproteins Driven by the Assessment of protein surface reactivity. *RSC Adv.* 2014;4(99):56455–65.
36. Bernardini R, Aufferi R, Detcheva A, Recchia S, Cicconi R, Amicosante M, et al. Neonatal protection and preterm birth reduction following maternal group B streptococcus vaccination in a mouse model. *J Matern Fetal Neonatal Med.* 2017;30(23):2844–50.
37. Anish C, Schumann B, Pereira CL, Seeberger PH. Chemical biology approaches to designing defined carbohydrate vaccines. *Chem Biol.* 2014;21(1):38–50.
38. Broecker F, Martin CE, Wegner E, Mattner J, Baek JY, Pereira CL, et al. Synthetic lipoteichoic acid glycans are potential vaccine candidates to protect from *Clostridium difficile* infections. *Cell Chem Biol.* 2016;23(8):1014–22.
39. Emmadi M, Khan N, Lykke L, Reppe K, S GP, Lisboa MP, et al. A Streptococcus pneumoniae type 2 Oligosaccharide Glycoconjugate elicits Opsonic antibodies and is protective in an animal model of Invasive Pneumococcal Disease. *J Am Chem Soc.* 2017;139(41):14783–91.
40. Leelayuwapan H, Kangwanransan N, Chawengkirttikul R, Ponpuak M, Charlermroj R, Boonyarattanakalin K, et al. Synthesis and immunological studies of the Lipomannan Backbone glycans found on the Surface of *Mycobacterium tuberculosis*. *J Org Chem.* 2017;82(14):7190–9.
41. Maeda N, Nigou J, Herrmann JL, Jackson M, Amara A, Lagrange PH, et al. The cell surface receptor DC-SIGN discriminates between *Mycobacterium* species through selective recognition of the mannose caps on lipoarabinomannan. *J Biol Chem.* 2003;278(8):5513–6.
42. Chatterjee D, Khoo KH. Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with profound physiological effects. *Glycobiology.* 1998;8(2):113–20.
43. Perley CC, Frahm M, Click EM, Dobos KM, Ferrari G, Stout JE, et al. The human antibody response to the surface of *Mycobacterium tuberculosis*. *PLoS ONE.* 2014;9(2):e98938.
44. Tessema TA, Bjune G, Hamasur B, Svenson S, Syre H, Bjorvatn B. Circulating antibodies to lipoarabinomannan in relation to sputum microscopy, clinical features and urinary anti-lipoarabinomannan detection in pulmonary tuberculosis. *Scand J Infect Dis.* 2002;34(2):97–103.
45. Shete PB, Ravindran R, Chang E, Worodria W, Chaisson LH, Andama A, et al. Evaluation of antibody responses to panels of *M. Tuberculosis* antigens as a screening tool for active tuberculosis in Uganda. *PLoS ONE.* 2017;12(8):e0180122.
46. de Valliere S, Abate G, Blazevic A, Heuertz RM, Hoft DF. Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies. *Infect Immun.* 2005;73(10):6711–20.
47. Chen T, Blanc C, Eder AZ, Prados-Rosales R, Souza AC, Kim RS, et al. Association of Human Antibodies to Arabinomannan with enhanced mycobacterial opsonophagocytosis and intracellular growth reduction. *J Infect Dis.* 2016;214(2):300–10.
48. Correia S, Silva V, Garcia-Diez J, Teixeira P, Pimenta K, Pereira JE, et al. One Health Approach reveals the absence of Methicillin-Resistant *Staphylococcus aureus* in Autochthonous Cattle and their environments. *Front Microbiol.* 2019;10:2735.
49. Glatman-Freedman A, Casadevall A, Dai Z, Jacobs WR Jr, Li A, Morris SL, et al. Antigenic evidence of prevalence and diversity of *Mycobacterium tuberculosis* Arabinomannan. *J Clin Microbiol.* 2004;42(7):3225–31.
50. Haile M, Kallenius G. Recent developments in Tuberculosis vaccines. *Curr Opin Infect Dis.* 2005;18(3):211–5.
51. Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. *Tuberculosis (Edinb).* 2005;85(1–2):29–38.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.